Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 16/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.41 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8075467 | 1.00 | SLC6A9 (0.48) | SLC6A9MEN1KMT2AHCRTR2NPC1 | |
| SCHEMBL8088678 | 1.00 | SLC6A9 (0.48) | SLC6A9MEN1KMT2AHCRTR2NPC1 | |
| SCHEMBL13970170 | 0.91 | SLC6A9 (0.47) | SLC6A9NPC1RAB9ASLC6A5 | |
| SCHEMBL8091759 | 0.85 | SLC6A9 (0.67) | SLC6A9SLC6A5 | |
| SCHEMBL8085504 | 0.85 | SLC6A9 (0.67) | SLC6A9SLC6A5 | |
| SCHEMBL8086275 | 0.83 | SLC6A9 (0.46) | SLC6A9SLC6A5 | |
| SCHEMBL13970230 | 0.83 | SLC6A9 (0.58) | SLC6A9SLC6A5 | |
| SCHEMBL8086589 | 0.82 | SLC6A9 (0.52) | SLC6A9MEN1KMT2ASLC6A5 | |
| SCHEMBL13970248 | 0.82 | SLC6A9 (0.53) | SLC6A9SLC6A5 | |
| SCHEMBL8086612 | 0.82 | SLC6A9 (0.55) | SLC6A9SLC6A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090030033-A1 | Novel Compounds 894 | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030033-A1 | Novel Compounds 894 | AZI2, TPMT, AMPD2 | SLC6A9 4382/4885MEN1 3176/4885KMT2A 904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.